SEARCH:   Advanced

Blood, 15 November 2004, Vol. 104, No. 10, pp. 3078-3085. Prepublished online as a Blood First Edition Paper on July 29, 2004; DOI 10.1182/blood-2004-03-1036. This Article Full Text (PDF) All Versions of this Article: 2004-03-1036v1 104/10/3078    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kern, W. Articles by Haferlach, T. Search for Related Content PubMed PubMed Citation Articles by Kern, W. Articles by Haferlach, T. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 18, 2004 Accepted July 13, 2004 Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia Wolfgang Kern*, Daniela Voskova, Claudia Schoch, Wolfgang Hiddemann, Susanne Schnittger, and Torsten Haferlach Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Muenchen, Germany * Corresponding author; email: Wolfgang.Kern{at}med.uni-muenchen.de. Quantification of minimal residual disease (MRD) reveals significant prognostic information in patients treated for acute myeloid leukemia (AML). The application of multiparameter flow cytometry (MFC) for MRD assessment has resulted in significant prognostic information in selected cases in previous analyses. We analyzed MRD in unselected patients with AML in complete remission (CR) after induction (n=58) and consolidation (n=62) therapies. By using a comprehensive panel of monoclonal antibodies we identified at least one leukemia-associated aberrant immunophenotype (LAIP) in each patient. The degree of reduction between diagnosis and CR in LAIP-positive cells (log-difference, LD) as a continuous variable was significantly related to relapse-free survival (RFS) both after induction (p=0.0001) and consolidation (0.00008) therapies, respectively. The LD determined after consolidation therapy was the only parameter related to overall survival (OS; p=0.005). Separation of patients based on the 75-percentile of LD after consolidation therapy resulted in groups with highly different RFS (83.3% vs. 25.7%, p=0.0034) and OS (87.5% vs. 51.4%, p=0.0507) at two years. Multivariate analysis identified LD as independent prognostic factor for RFS at both checkpoints. MFC-based quantification of MRD reveals important prognostic information in unselected patients with AML in addition to cytogenetics and should be further evaluated and used in clinical trials. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Cilloni, F. Messa, F. Arruga, I. Defilippi, E. Gottardi, M. Fava, S. Carturan, R. Catalano, E. Bracco, E. Messa, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy Haematologica, June 1, 2008; 93(6): 921 - 924. [Abstract] [Full Text] [PDF] U. Bacher, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients Blood, March 1, 2008; 111(5): 2527 - 2537. [Abstract] [Full Text] [PDF] A. van Rhenen, G. A. M. S. van Dongen, A. Kelder, E. J. Rombouts, N. Feller, B. Moshaver, M. S.-v. Walsum, S. Zweegman, G. J. Ossenkoppele, and G. Jan Schuurhuis The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells Blood, October 1, 2007; 110(7): 2659 - 2666. [Abstract] [Full Text] [PDF] C. Langebrake, U. Creutzig, M. Dworzak, O. Hrusak, E. Mejstrikova, F. Griesinger, M. Zimmermann, and D. Reinhardt Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group J. Clin. Oncol., August 1, 2006; 24(22): 3686 - 3692. [Abstract] [Full Text] [PDF] D. Steinbach, A. Schramm, A. Eggert, M. Onda, K. Dawczynski, A. Rump, I. Pastan, S. Wittig, N. Pfaffendorf, A. Voigt, et al. Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia Clin. Cancer Res., April 15, 2006; 12(8): 2434 - 2441. [Abstract] [Full Text] [PDF] A. van Rhenen, N. Feller, A. Kelder, A. H. Westra, E. Rombouts, S. Zweegman, M. A. van der Pol, Q. Waisfisz, G. J. Ossenkoppele, and G. J. Schuurhuis High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival Clin. Cancer Res., September 15, 2005; 11(18): 6520 - 6527. [Abstract] [Full Text] [PDF] T. Haferlach, A. Kohlmann, S. Schnittger, M. Dugas, W. Hiddemann, W. Kern, and C. Schoch Global approach to the diagnosis of leukemia using gene expression profiling Blood, August 15, 2005; 106(4): 1189 - 1198. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020